37 results about "Microvascular endothelium" patented technology

The invention provides a microfluidic chip, system and method for osteochondral organs, and relates to the technical field of organoid microfluidic chips, the chip comprises a bone microvascular endothelial cell channel, a bone compartment, a cartilage compartment and a synovial fluid channel which are arranged in parallel and in sequence, and permeation areas between the channel and the compartments and between the compartments. According to the scheme, the complex structure and function of a human osteochondral system are effectively simulated, the physiological and pathological processes of human bone joints can be simulated more truly in an in-vitro environment, and a method for establishing a highly-simulated femoral head necrosis model and osteoarthritis model based on the chip is provided. The problems that a traditional model is insufficient in physiological environment simulation, lack of control over dynamic culture conditions, tedious and time-consuming in the construction process, difficult to support high-throughput experiments and the like are solved.

The invention provides an application of a lactic acid modified histone H3 in preparation of a product for treating and / or preventing lung microvascular endothelial cell dysfunction, and the lactic acid modified histone H3 is obtained by carrying out lactic acid modification on the 14th amino acid of histone, the lung microvascular endothelial cell dysfunction is sepsis mediated lung microvascular endothelial cell dysfunction. The invention provides a new idea for the treatment of sepsis-mediated lung microvascular endothelial cell dysfunction.

The invention relates to application of sea cucumber-derived nano-vesicles in preparation of a medicine for promoting wound repair. The nano-vesicles (SC-EVs) extracted and prepared from sea cucumbers can effectively promote cell migration, scratch repair and tube forming capabilities of human skin epithelial cells (HACAT) and human skin microvascular endothelial cells (HM DEC) and inhibit cell apoptosis, so that the capability of repairing cells is achieved, and particularly the effect of repairing wound surfaces in a high glucose state or diabetes mellitus is achieved. The invention provides a new direction and thought for the application of the sea cucumber-sourced nano vesicles (SC-EVs), provides a brand new drug research and development and clinical treatment direction for wound repair, especially for solving the problem of difficult healing of wounds of patients with high glucose or diabetes, and has extremely high social value and market application prospect.

The invention provides application of scEMC10 in treatment and diagnosis of cerebral vascular endothelial cell senescence, and relates to the technical field of biomedicine. The research of the inventor finds that brain microvascular endothelial cell senescence is caused by the lack of scEMC10; after the brain microvascular endothelial cells are treated by scEMC10, beta-galactosidase, SASP and classic senescence markers related to senescence can be down-regulated; after scEmc10 is supplemented to old mice and Alzheimer's disease 5XFAD model mice, the motion coordination ability and the spatial cognitive ability of the mice can be obviously improved, the relative content of a marker phosphorylated alpha-synuclein of the Parkinson's disease of the old mice can be obviously reduced, and the content of tyrosine hydroxylase phosphorylated active forms can be increased. Therefore, the scEMC10 can be used for treating brain microvascular endothelial cell senescence, improving Alzheimer's disease and Parkinson's disease and detecting brain microvascular endothelial cell senescence as a marker.

The invention discloses a PRP (platelet-rich plasma) stem cell exosome chitosan composition as well as a preparation method and application thereof. The PRP stem cell exosome chitosan composition comprises the following components: activated platelet-rich plasma, stem cell exosome and chitosan. The preparation method of the composite gel comprises the following steps: adding chitosan into a suspension containing activated platelet-rich plasma and stem cell exosome, uniformly mixing, adding a povidone suspending aid, oscillating to form a stable suspension state, adjusting the pH value to 7.5-7.8, mixing with thrombin and a calcium agent, stirring in a dark place, and solidifying to form a gelatinous substance, thereby obtaining the composite gel. The platelet-rich plasma-stem cell exosome-chitosan composite gel is obtained. The composition and the composite gel can promote microvascular endothelial cell regeneration and recover normal vascular endothelial morphology and functions; skin regeneration is promoted; broad-spectrum bacteriostasis and lipid reduction are realized, and local inflammation and immune response are inhibited.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition containing osmundone and application of the traditional Chinese medicine composition to preparation of medicines for preventing and treating diabetic complications. The invention provides a traditional Chinese medicine composition and an effect of osmundone serving as an active ingredient of the traditional Chinese medicine composition in preventing and treating diabetic complications caused by oxidative stress and / or abnormal proliferation of renal tubular cells. Experiments show that the osmundone or the traditional Chinese medicine composition can reduce microvascular endothelial cell injury caused by oxidative stress injury and inhibit abnormal proliferation of renal tubular cells.

The invention relates to a brain microvascular endothelial cell-derived exosome and a preparation method and application thereof, cerebral vascular endothelial cells are pretreated by ischemia and hypoxia, and the exosome rich in miRNA with a nerve and blood vessel protection effect can be efficiently prepared. The invention discloses a preparation method of a preferable vascular endothelial cell-derived exosome, which can be used for promoting the repair of nerve and blood vessel units in ischemic cerebrovascular diseases and has a potential wide application prospect.

The invention discloses a construction method of a coronary artery microcirculation disturbance cell model, and belongs to the technical field of biological medicine. According to the method, mouse heart microvascular endothelial cells (MCMEC) are taken as objects, tetrachlorohydroquinone (TCHQ) is used for treating for 6 hours at the concentration of 20-40 [mu] M, and CMD typical characteristics such as apoptosis, increase of reactive oxygen species (ROS), reduction of nitric oxide (NO) and release of inflammatory factors (TNF-alpha and IL-1beta) of the cells are induced. The TCHQ is applied to construction of the CMD model for the first time, and the model is stable, good in repeatability and capable of being used for CMD pathogenesis research and drug screening.

The application provides an application of scEMC10 in treatment and diagnosis of brain vascular endothelial cell aging, and relates to the technical field of biomedicine. The inventor finds that scEMC10 deficiency leads to brain microvascular endothelial cell aging; brain microvascular endothelial cells treated by scEMC10 can down-regulate beta-galactosidase, SASP and classic aging markers related to aging; after old mice and 5XFAD model mice of Alzheimer's disease are supplemented with scEmc10, the movement coordination ability and spatial cognitive ability of the mice can be obviously improved, and the relative content of the Parkinson's disease marker, phosphorylated alpha-synuclein, of the old mice can be obviously reduced, and the content of the tyrosine hydroxylase phosphorylation activity form can be increased. Therefore, scEMC10 can be used for treatment of brain microvascular endothelial cell aging, improvement of Alzheimer's disease and Parkinson's disease, and detection of brain microvascular endothelial cell aging as a marker.

The invention discloses an extraction and separation method of houttuynia cordata extract and its application. The extraction and separation method of houttuynia cordata extract comprises extracting houttuynia cordata with ethanol aqueous solution to obtain ethanol extract, recovering ethanol and concentrating, extracting with ethyl acetate, taking water phase to obtain ethyl acetate water part, and obtaining houttuynia cordata extract. The houttuynia cordata extract can be used to prepare drugs for preventing and treating chronic obstructive pulmonary disease, reduce the secretion of airway epithelial cell mucin MUC5AC, increase the activity of pulmonary microvascular endothelial cells, inhibit the apoptosis of pulmonary microvascular endothelial cells, reduce the number of lung tissue macrophages, and improve lung function.

The invention belongs to the technical field of protein engineering, and particularly relates to an active polypeptide for inhibiting diabetic retina microangiogenesis. The active polypeptide is SEQ ID NO: 1 formed by three core fragments through flexible linkage or a derivative sequence obtained by mutation in the core fragments. The group of active polypeptides can significantly inhibit the physiological processes of DNA synthesis, proliferation, migration, callus, tube formation and the like of retina microvascular endothelial cells in a high-glucose environment, thereby achieving the effect of inhibiting angiogenesis.

The present application relates to the technical field of nano-preparation, in particular to an extracellular vesicle-liposome hybrid nanoparticle and a preparation method and application thereof. The extracellular vesicle-liposome hybrid nanoparticle provided by the present application significantly improves the ability of drugs to cross the blood-brain barrier and the target enrichment efficiency of ischemic lesions in the brain through active targeting modification; the specific response release of drugs is realized by using the high active oxygen microenvironment of the lesion, non-specific distribution of drugs is reduced, and the systemic toxic side effects are reduced; ultimately, a multi-target point synergistic treatment system capable of synchronously regulating neural cell apoptosis, glial cell inflammatory activation, brain microvascular endothelial cell ferroptosis and the structural integrity of the blood-brain barrier is constructed, the problem that the effect of traditional single target point intervention is limited is broken through from the root, and a more efficient, safe and precise new treatment strategy is provided for cerebral ischemia-reperfusion injury.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 cells of mouse hippocampal neurons and hCMEC / D3 cells of human brain microvascular endothelium induced by oxygen-glucose deprivation (OGD), can resist the damage of corticosterone and MPP + induced PC12 cells, and effectively inhibits the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve vascular units.

The present invention provides an application of a gene detection reagent in the preparation of a kit for diagnosing diabetes mellitus complicated with coronary heart disease, belonging to the technical field of biomedicine. The detection reagent provided by the present invention is a reagent for detecting the expression level of LncRNA-AC141930.2. By detecting the expression level of LncRNA-AC141930.2, it is possible to detect at an early stage whether a type 2 diabetes patient is complicated with coronary heart disease. At the same time, the siRNA provided by the present invention can effectively reduce the senescence of human microvascular endothelial cells caused by high glucose and can reduce the decline in the tube formation ability of human microvascular endothelial cells caused by high glucose. Therefore, it can be used in the preparation of drugs for treating diabetes mellitus complicated with coronary heart disease.

The invention belongs to the technical field of disease treatment, and particularly relates to a composition for regulating blood sugar and microvascular homeostasis and a preparation method thereof. The composition for regulating the blood sugar and the microvascular homeostasis is prepared from the following components in parts by mass: 380 to 520 parts of peony seed oil, 260 to 440 parts of dihydromyricetin and 0.025 to 0.062 part of chromium picolinate. The composition for regulating blood sugar and microvascular homeostasis can be used for protecting microvessels, regulating blood sugar, improving microcirculation of the whole body and preventing diabetic complications, and is suitable for preventing and treating diseases such as hyperglycemia, hyperlipidemia and glycolipid metabolism syndrome. Experiments on vascular endothelial dysfunction of obese rats show that the composition disclosed by the invention can be used for remarkably improving microvascular endothelial functions of the obese rats and effectively delaying rise of arterial blood pressure. Experiments on mouse diabetic cardiomyopathy find that the composition has a definite myocardial protection effect on DCM mice.

The invention belongs to the technical field of molecular biology, and discloses application of DDX24 in maintaining the homeostasis of an intestinal vascular barrier. According to the present invention, the low expression of the intestinal microvascular endothelial DDX24 in the inflammatory bowel disease (IBD) is firstly found so as to construct the adult endothelial cell specific DDX24 induced knockout mouse model, the homeostasis of the intestinal vascular barrier (GVB) of the mouse is imbalanced, and the mouse suffers from spontaneous enteritis, such that the intestinal microvascular endothelial cell DDX24 is the important molecule for maintaining the intestinal homeostasis; and mechanism research finds that the intestinal microvascular endothelial cell DDX24 inhibits cell senescence to protect the GVB steady state. The research discloses an important mechanism of DDX24 for protecting GVB homeostasis by inhibiting intestinal microvascular endothelial cell senescence for the first time, and provides a strategy and basis for clinical diagnosis and treatment of IBD vascular barrier.

The present disclosure provides a microvascular endothelial function detection method, device, electronic device and storage medium, the method comprising: obtaining a target user's basic blood oxygen saturation, a blood oxygen saturation net recovery time and a blood perfusion index increase; determining a vascular endothelial function abnormality index according to the basic blood oxygen saturation, the blood oxygen saturation net recovery time and the blood perfusion index increase; when the vascular endothelial function abnormality index is greater than an abnormality index threshold, determining that the target user has vascular endothelial dysfunction.

To provide a blood-brain barrier model using a human immortalized cell, and a method for producing the same.SOLUTION: A method for producing a multicellular blood-brain barrier model includes: (i) a culture step of disseminating human conditional immortalized pericytes onto a first culture medium to culture the pericytes; (ii) a pericyte differentiation step of differentiating the cultured human conditional immortalized pericyte on a second culture medium; (iii) an astrocyte culture step of disseminating human conditional immortalized astrocytes onto a third culture medium to culture the astrocytes; (iv) an astrocyte differentiation step of differentiating the cultured human conditional immortalized astrocytes on a fourth culture medium; and (v) a brain microvascular endothelial cell culture step of disseminating human conditional immortalized brain microvascular endothelial cells onto a fifth culture medium to culture the disseminated human conditional immortalized brain microvascular endothelial cells.SELECTED DRAWING: Figure 2A

This invention belongs to the field of organ-on-a-chip technology, providing a blood-brain barrier / neuronal co-culture chip, an organ-on-a-chip, its construction method, and applications. The blood-brain barrier / neuronal co-culture chip provided by this invention includes a reservoir, vascular endothelial channels, a hydrogel chamber, and a brain region microenvironment channel. The vascular endothelial channels are used for seeding brain microvascular endothelial cells; the hydrogel chamber is used for seeding brain perivascular cells and astrocytes, and exchanges substances with the vascular endothelial channels through a porous membrane; the brain region microenvironment channel is used for seeding neurons, constructing a three-dimensional neuronal network growth environment. Using this blood-brain barrier / neuronal co-culture chip as the chip body, the construction of the blood-brain barrier, the glial support microenvironment, and the three-dimensional developmental space of neurons can be realized, achieving dynamic interaction between the blood-brain barrier and the neuronal microenvironment. It has broad application prospects in the study of the mechanisms of nervous system diseases and the evaluation of nervous system drugs.

This invention discloses an siRNA that slows down endothelial-mesenchymal transition (EMT) and a cell line with low GTF2H4 expression. The invention provides three siRNAs that knock down GTF2H4 expression using RNAi, with sequences shown in SEQ ID NO: 1-6. It also provides shRNAs with sequences shown in SEQ ID NO: 13-14, and constructs a microvascular endothelial cell line with low GTF2H4 expression based on these sequences. This cell line significantly inhibits hypoxia-induced EMT, suppresses cell migration, and promotes cell tube formation. This provides new hope for clinical intervention in EMT to improve cardiovascular disease and facilitates further research to explore the potential molecular mechanisms between GTF2H4 and EMT, offering useful clues for treating cardiovascular diseases caused by EMT and possessing significant application value.

The invention relates to the technical field of cell sensing, and discloses a brain microvascular endothelial cell injury assessment method, which comprises the following steps of: synchronously acquiring a metabolic vibration signal and a transcellular resistance signal of brain microvascular tissues through a sensor carrier integrating a piezoelectric sensing unit and an electrode unit, and calculating a correlation coefficient of time domain envelope of the signals; the cell damage state is judged based on continuous negative correlation, early warning of cell function instability is achieved through double-signal dynamic coupling analysis, a harmonic phase locking recognition mechanism can capture the recessive pathological state in the compensation period, and signal entropy change compensation enables the system to have the capacity of self-adaption to environment interference. And a real-time and accurate capillary function evaluation means is provided for clinic.

The present invention relates to the application of sea cucumber-derived nanovesicles in the preparation of drugs for promoting wound repair. The nanovesicles (SC-EVs) extracted and prepared from sea cucumbers of the present invention can effectively promote the cell migration, scratch repair, and tube formation ability of human skin epithelial cells (HACAT) and human skin microvascular endothelial cells (HM DEC), and inhibit cell apoptosis, thereby achieving the ability to repair cells, especially the repair effect on wounds under high sugar conditions or diabetic wounds. The present invention provides a new direction and idea for the application of sea cucumber-derived nanovesicles (SC-EVs), and provides a new direction for drug research and development and clinical treatment for wound repair, especially for overcoming the problem of difficult wound healing in patients with high sugar or diabetes, and has extremely high social value and market application prospects.

Provided is a technology allowing for stable supply of brain microvascular endothelium-like cells. This coating agent for inducing differentiation of pluripotent stem cells into brain microvascular endothelium-like cells contains at least one component of a Laminin-221 fragment or an N-terminal Vitronectin.

The invention provides a multi-system microvessel co-culture micro-fluidic chip and a preparation method thereof, and belongs to the technical field of biomedical engineering and microfluidics. The adipose-derived stem cells are introduced for the first time to participate in the cell culture environment in the chip, the difference between the in-vitro microvascular network micro-fluidic chip and the in-vivo microenvironment of a human body is further reduced, and the in-vivo environment is better simulated in vitro. In addition, different micro-fluidic chip monomers are constructed by using three different representative vascular endothelial cells, namely human brain microvascular endothelial cells (HBMVEC), human umbilical vein endothelial cells (HUVEC) and human lung microvascular endothelial cells (HPMVEC), and the micro-fluidic chip is obtained by connecting all the monomers. The conditions of microvascular endothelium between different systems can be known and compared at the same time.

Provided is a fluidic chip, comprising: a bottom region, the bottom region comprising a central channel and at least one side channel adjacent thereto, the central channel having therein a plurality of cells disposed in a matrix; and a middle region, the middle region having a chamber defined therein, the chamber optionally being an open-top chamber, the chamber being in register with at least one of the central channel and the at least one side channel of the bottom region. Also provided is a method, comprising co-culturing airway epithelial cells, pulmonary microvascular endothelial cells, and lung fibroblasts using a fluidic chip; the airway epithelial cells comprising airway cells or alveolar cells. Also disclosed is causing contact between (1) at least one of an agent and a stimulus, and (2) epithelial cells disposed within the chamber of a fluidic chip, and monitoring at least one marker indicative of exposure of the epithelial cells to the sample.

The invention discloses a co-culture solution, a construction method of an in-vitro organ-like model, the in-vitro organ-like model and application of the in-vitro organ-like model, and belongs to the technical field of biological medicine. The DMEM culture medium contains 4-hydroxyethylpiperazine ethanesulfonic acid, L-alanyl-L-glutamine, an N2-additive, a G-5 additive, a B-27 additive, a human epidermal growth factor, penicillin-streptomycin and fetal calf serum, and the MCEB131 culture medium is used for culturing the human epidermal growth factor, the penicillin-streptomycin and the fetal calf serum. The co-culture solution provided by the invention can realize co-culture of human astrocytes SVGP12, human microvascular endothelial cells HMEC-1 and human perineuronal cells HBVP, avoids the interference of cross components of different nutrient solutions on the cells, and improves the stability of an in-vitro organ-like model.

The invention discloses a targeting microbubble for targeting microvascular endothelium as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The targeted microvesicle of the targeted microvascular endothelium provided by the invention comprises a biotinylated liposome microvesicle combined with streptavidin and a biotinylated carbonic anhydrase 4 antibody, the biotinylated liposome microbubble combined with streptavidin takes lipid as a shell membrane material, fluorinated inert gas is wrapped in the shell membrane material, and the surface of the shell membrane material is combined with streptavidin; and the shell membrane material is prepared from DSPC (Distearoyl Pyrrolidone), DSPE-PEG (Polyethylene Glycol) 2000 and DSPE-PEG 2000-biotin. The targeting microbubble has good targeting property, biocompatibility and safety, and can intuitively reflect the density difference of microvessels, thereby providing an intuitive and reliable imaging basis for early diagnosis and disease assessment of coronary artery microvascular diseases.

The invention discloses an extraction and separation method and application of a herba houttuyniae extract. The extraction and separation method of the herba houttuyniae extract comprises the following steps: extracting a herba houttuyniae medicinal material with an ethanol water solution to obtain an ethanol extracting solution, recovering ethanol, concentrating, extracting with ethyl acetate, and taking a water phase to obtain an ethyl acetate water part, namely the herba houttuyniae extract. The herba houttuyniae extract can be used for preparing medicines for preventing and treating chronic obstructive pulmonary disease, reducing secretion of airway epithelial cell mucoprotein MUC5AC, improving lung microvascular endothelial cell activity, inhibiting lung microvascular endothelial cell apoptosis, reducing the number of lung tissue macrophages and improving lung functions.

The invention discloses an application of an exosome carrying miR-125a-5p in acute lung injury, and belongs to the technical field of biological medicines. The invention proposes that the miR-125a-5p and the human umbilical cord mesenchymal stem cell source carrying the miR-125a-5p exosome can be used for treating the acute lung injury for the first time; the miR-125a-5p and the human umbilical cord mesenchymal stem cell source carrying the miR-125a-5p exosome can improve the development process of the mouse acute lung injury by means of reducing lung microvascular endothelial cell ferroptosis, reducing expression of intercellular adhesion molecules and improving lung inflammation, and a new thought is provided for the pathogenesis of the acute lung injury. The research on related mechanisms of occurrence and development of the acute lung injury is further perfected. According to the invention, a theoretical basis and related experimental data support can be provided for clinical early diagnosis, early treatment and future development of targeted miRNA drugs and treatment of acute lung injury.

Described herein is a biocompatible lipid nanoparticle (LNP) composition suitable for delivering RNA payloads into cells and tissues of a subject. The biocompatible LNPs comprise an ionizable cationic lipid as a core component and have a net neutral surface charge at physiological pH. Delivery of LNP-encapsulated siRNA inhibiting the expression Spermidine / spermine N1-acetyltransferase 1 (SAT1) is shown to inhibit proliferation of a glioblastoma cell line, but not in other cells pertinent to brain tissue such as microvascular endothelial cells, primary human astrocytes, and macrophage cells. Use of a cadherin-binding peptide to increase delivery of LNP-encapsulated siRNA across a blood-brain barrier monolayer model is also described.